Recent advances in systemic therapy for hepatocellular carcinoma
Abstract Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially with conventional cytotoxic drugs, is usually ineffective. For more than a decade, sorafenib has been the only...
Main Authors: | Huajun Zhang, Wuyang Zhang, Longying Jiang, Yongheng Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-01-01
|
Series: | Biomarker Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40364-021-00350-4 |
Similar Items
-
Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives
by: Daniel M. Girardi, et al.
Published: (2023-03-01) -
Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
by: Shuqi Xie, et al.
Published: (2023-05-01) -
Corrigendum: Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
by: Shuqi Xie, et al.
Published: (2023-12-01) -
A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma
by: Angelica Singh, et al.
Published: (2022-09-01) -
Immunotherapy and the Combination with Targeted Therapies for Advanced Hepatocellular Carcinoma
by: Carmelo Laface, et al.
Published: (2023-01-01)